European Journal of Medicinal Chemistry p. 562 - 575 (2019)
Update date:2022-08-30
Topics:
Yan, Zhiqiang
Chong, Shuyi
Lin, Huiyun
Yang, Qian
Wang, Xin
Zhang, Weidong
Zhang, Xiaokun
Zeng, Zhiping
Su, Ying
Nuclear receptor RXRα plays an important role in many biological and pathological processes. The nongenomic action of RXRα is implicated in many cancers. K-8008, a non-canonical RXRα ligand derived from sulindac, inhibits the TNFα-activated PI3K/AKT pathway by mediating the interaction between a truncated form of RXRα (tRXRα) and the p85α regulatory subunit of PI3K and exerts potent anticancer activity in animal model. Herein we report our studies of a novel series of K-8008 analogs as potential anticancer agents targeting RXRα. Two compounds 8b and 18a were identified to have slightly stronger binding to RXRα and improved apoptotic activities in breast cancer cells.
View MoreDaicel Chiral Technologies (China)CO.,LTD
Contact:021-5046-0086*8
Address:Part C, FL 5, the 16th Building, No. 69, XiYa Road, WaiGaoQiao Free Trade Zone, Shanghai, 200131, P.R.China
FREEBARQUE DEVELOPMENT GROUP LIMITED
Contact:+86(0)10-5109 5335 or 5109 5345
Address:Room602,Block1-B,LINGDI OFFICE,NO.13 BEIYUAN ROAD
Shanghai Yudiao Chemistry Technology Co.,Ltd
Contact:0086-18964703211
Address:Building NO.5, NO.218,Rongtian Road,ganxiang town,Jinshan District,shanghai,201518,china
Yurui(Shanghai)Chemical Co.,Ltd
Contact:0086 21-50456736
Address:No.3188 Xiupu Road,Shanghai
Beijing Mashi Fine Chemical Co.,Ltd.
Contact:+86-10-61271592
Address:Room 506, Section B, Kaichi Mansion, Industrial Development
Doi:10.1007/BF00497211
(1990)Doi:10.1021/acs.orglett.6b02301
(2016)Doi:10.1016/j.tetlet.2007.07.018
(2007)Doi:10.1021/jp9609500
(1997)Doi:10.1021/acscatal.1c02140
(2021)Doi:10.1021/jo01273a080
(1968)